New Model Using Ferroptosis-Related Genes Predicts Survival in Diffuse Large B-Cell Lymphoma
Researchers sought to determine the prognostic value of genes related to ferroptosis in DLBCL.
Diagnosis & Disease Information
Zamtocabtagene Autoleucel Produces High ORR in Relapsed/Refractory DLBCL
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
Chronotherapy Study Shows Afternoon Regimens Better for Female Patients With DLBCL
A study evaluating the use of chronotherapy for hematologic cancers identifies how the approach can improve outcomes for some patients.
“Severe4” Predicts Outcomes of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
Clinical Trials Testing Novel Combinations in Diffuse Large B-Cell Lymphoma
Researchers are conducting phase 2 and 3 trials to investigate novel treatment combinations for patients with DLBCL.
Epcoritamab Shows Promise in Large B-Cell Lymphoma
Researchers sought to determine whether epcoritamab would be an effective treatment among patients with relapsed or refractory large B-cell lymphoma.
Polatuzumab Vedotin Combined With Chemoimmunotherapy Is Provisionally Cost-Effective in Untreated Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether pola-R-CHP would be cost-effective compared with R-CHOP for first-line treatment of DLBCL.
Rapcabtagene Autoleucel Shows Activity in Relapsed/Refractory DLBCL
Rapcabtagene autoleucel may elicit durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Routine Use of Axicabtagene Ciloleucel Could Be Cost Effective in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether the use of second-line CAR-T therapy could be cost effective in DLBCL.
Standard of Care More Likely to Be Cost-Effective Than CAR-T Therapy in DLBCL
Researchers sought to determine the cost-effectiveness of CAR-T therapy compared with standard of care in patients with DLBCL.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...